Global NK Cell Therapy Market Outlook, 2031

The global NK cell therapy industry covers treatments that use natural killer cells, innate immune cells that can kill cancer cells and infected cells without prior sensitisation, as therapeutic products. NK cells can be sourced from donor peripheral blood, umbilical cord blood, induced pluripotent stem cells or established cell lines such as NK-92, and they can be used unmodified, expanded and activated, or engineered with chimeric antigen receptors, known as CAR-NK, or with enhancements such as cytokine support, high-affinity CD16 receptors and deletion of inhibitory genes. Because NK cells rarely cause graft-versus-host disease or severe cytokine release syndrome, they can be manufactured from healthy donors in large batches and stored as off-the-shelf products, offering potential advantages in cost and accessibility over autologous CAR-T. Developers include Artiva Biotherapeutics, Nkarta, Fate Therapeutics, Century Therapeutics, ImmunityBio, NKGen Biotech, Glycostem, GC Cell, Celularity, Takeda and many Chinese companies. ImmunityBio's Anktiva, an IL-15 superagonist approved by the FDA in April 2024 for bladder cancer, activates NK and T cells and is often associated with the field, although it is not a cell therapy. No engineered NK cell therapy has yet received approval in the United States or Europe.

NK cell therapy has shifted focus significantly since 2023. Early clinical studies in blood cancers showed that NK and CAR-NK cells were safe but often produced shorter responses than CAR-T, and several companies reduced oncology programmes; Nkarta and Fate Therapeutics refocused on autoimmune disease in 2024, and Takeda deprioritised its CAR-NK programme. At the same time, the success of CAR-T in lupus and other autoimmune diseases suggested that deep B-cell depletion could reset the immune system, and off-the-shelf NK cells, given without the risks and complexity of CAR-T, became an attractive alternative. Artiva's AlloNK, a non-engineered cord blood-derived NK cell therapy given with rituximab, reported that 71% of refractory rheumatoid arthritis patients with six months of follow-up achieved ACR50 responses in data presented at EULAR in June 2026, received FDA regenerative medicine advanced therapy designation and plans to start a phase 3 trial in the second half of 2026, potentially becoming the first B-cell depleting cell therapy in phase 3 for rheumatoid arthritis. Nkarta is testing its CD19 CAR-NK therapy NKX019 across lupus nephritis, systemic sclerosis, myositis, vasculitis and other conditions, with outpatient community dosing agreed with the FDA. In oncology, NK cells are being combined with antibodies, cytokines and checkpoint inhibitors, and iPSC-derived NK platforms from Fate and Century aim to provide uniform engineered products at scale.

Market Dynamics Market Drivers • Off-the-Shelf Potential and Favourable SafetyNK cells from healthy donors do not typically cause graft-versus-host disease and have lower rates of severe cytokine release syndrome and neurotoxicity than CAR-T. This allows manufacture of large batches from one donor, cryopreservation and immediate availability, potentially at lower cost and with outpatient administration. These features make NK therapies attractive for treating many patients, including in community settings.
• Expansion into Autoimmune DiseaseEvidence that deep B-cell depletion can produce remissions in autoimmune diseases has created a large new opportunity for NK cell therapies, which can be combined with B-cell targeting antibodies or engineered with CD19 CARs. Early data in rheumatoid arthritis, lupus, Sjögren's disease and systemic sclerosis, regulatory designations and FDA alignment on phase 3 designs support investment in autoimmune NK programmes.

Market Challenges • Limited Persistence and DurabilityInfused NK cells often persist in the body for only weeks, which may limit the durability of responses, particularly in cancer. Many trials require repeated doses, lymphodepleting chemotherapy or cytokine support. Early oncology data were less impressive than CAR-T, leading some companies to cut programmes, and proving long-term benefit in autoimmune disease will require larger, controlled trials.
• Manufacturing, Scale and FundingExpanding and engineering NK cells efficiently is technically difficult, and genetic modification of NK cells is less efficient than for T cells. Producing consistent products at scale requires investment in manufacturing and quality systems. Biotechnology funding pressures have led to restructurings, layoffs and closures among NK cell companies, and the field lacks an approved engineered product to validate the approach.

Market Trends • B-Cell Depletion in Autoimmune DiseaseNK cell developers increasingly target autoimmune diseases, using either unmodified NK cells combined with anti-CD20 antibodies or CD19 CAR-NK cells, to achieve deep B-cell depletion without the toxicity and complexity of CAR-T. Trials cover rheumatoid arthritis, lupus nephritis, systemic sclerosis, myositis, Sjögren's disease, ANCA-associated vasculitis and membranous nephropathy, and outpatient community administration is a key differentiator.
• iPSC-Derived and Multiplex-Engineered NK CellsInduced pluripotent stem cells allow production of uniform NK cells from a single engineered master cell line, enabling multiple genetic modifications such as CARs, high-affinity CD16, IL-15 signalling and deletion of CD38 or CISH to improve function and persistence. Fate Therapeutics and Century Therapeutics lead this approach, and combinations with monoclonal antibodies that engage NK cells are being studied.



Segment Analysis Non-engineered NK cell therapies form an important and advancing segment, while CAR-NK and other engineered NK therapies represent the main area of innovation. Non-engineered NK cell therapies use NK cells expanded and activated from donor blood or cord blood, sometimes combined with monoclonal antibodies such as rituximab that direct NK cells to targets through the CD16 receptor. Artiva's AlloNK is the most advanced, moving into phase 3 in rheumatoid arthritis, and several Asian companies offer expanded NK cells in cancer. CAR-NK therapies express chimeric antigen receptors targeting CD19, BCMA, CD70 or other antigens and include Nkarta's NKX019 and programmes from Fate, Century and Chinese companies, often with additional engineering such as membrane-bound IL-15. Other engineered NK therapies add high-affinity CD16, cytokine genes or deletions of inhibitory molecules to boost activity when combined with antibodies. NK cell engagers, which are antibody-based molecules that direct a patient's own NK cells to tumours, form an adjacent drug segment. Autologous NK cell therapies, such as NKGen's programme in neurodegenerative disease, are a smaller category. NK cell lines, including NK-92 derivatives, provide consistent starting material.

Cord blood and peripheral blood are the main sources of NK cells today, while induced pluripotent stem cells are an important emerging source. Umbilical cord blood provides NK cells that can be expanded to large numbers, and it is used by Artiva, Takeda's former programme and many academic groups; one cord blood unit can produce many doses. Peripheral blood from healthy donors is widely used, including by Nkarta, allowing selection of donors with favourable NK cell characteristics. Induced pluripotent stem cells provide an unlimited, uniform source that can be engineered once and used to produce consistent products, and Fate Therapeutics and Century Therapeutics use this approach, although iPSC-derived NK cells may differ in maturity. NK cell lines, such as NK-92 and its derivatives, can be grown indefinitely but must be irradiated before infusion, limiting persistence. Autologous NK cells from patients themselves are used in some programmes. Placental sources have also been explored. The choice of source affects manufacturing scale, product consistency, engineering options and cost, and developers are optimising expansion methods using feeder cells, cytokines and bioreactors.

Haematological cancers and autoimmune diseases are the leading clinical focus areas for NK cell therapy, while solid tumours and other conditions represent further opportunities. Haematological cancers, including non-Hodgkin lymphoma, acute myeloid leukaemia, multiple myeloma and chronic lymphocytic leukaemia, were the first focus of NK cell therapy, with CAR-NK targeting CD19 and BCMA and NK cells used after stem cell transplantation to reduce relapse. Autoimmune diseases have become a major focus since 2024, including rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, systemic sclerosis, idiopathic inflammatory myopathy, Sjögren's disease, ANCA-associated vasculitis and membranous nephropathy, where NK therapies aim to deplete autoreactive B cells. Solid tumours, including ovarian, lung, liver, glioblastoma and gastrointestinal cancers, are targeted with NK cells combined with antibodies, checkpoint inhibitors or CARs, though tumour environments suppress NK activity. Infectious diseases, including viral infections after transplantation, and neurodegenerative diseases such as Alzheimer's disease, in NKGen's studies, form smaller areas. Ageing and senescent cell clearance are early research areas. Bladder cancer benefits from NK activation by Anktiva, although this is a drug rather than a cell therapy.

Hospitals and academic medical centres are the main end users of NK cell therapies, while outpatient and community rheumatology and oncology settings are emerging as important sites. Hospitals and academic medical centres conduct most NK cell therapy trials, particularly those involving lymphodepletion and cancer patients, and they have the cell therapy infrastructure required for handling and infusion. Specialised cancer centres run oncology trials combining NK cells with antibodies and other therapies. Community rheumatology and oncology practices are becoming important for autoimmune NK programmes designed for outpatient administration, and Nkarta has reached agreement with the FDA on community-based dosing, while Artiva highlights suitability for community rheumatology settings. Contract manufacturing organisations and in-house facilities produce NK cells at scale. Research institutes and universities, including MD Anderson Cancer Center, which developed cord blood CAR-NK technology licensed to Takeda, drive innovation. Cord blood banks supply starting material. In Japan, South Korea and China, some clinics offer NK cell treatments under regenerative medicine or other regulatory frameworks, sometimes with limited evidence, prompting regulatory attention.

Regional Analysis North America leads NK cell therapy development because of its concentration of NK cell companies, clinical trials and investment, while Asia-Pacific, particularly China, South Korea and Japan, is a major and fast-growing centre of NK cell research and clinical use. North America, led by the United States, is the leading region for NK cell therapy development, home to Artiva, Nkarta, Fate, Century, ImmunityBio and NKGen, and to academic centres such as MD Anderson and the University of Minnesota that pioneered NK therapies. FDA regenerative medicine advanced therapy designations, such as Artiva's for rheumatoid arthritis in 2026, and agreements on phase 3 and community dosing designs support progress. Funding pressures since 2022 have caused restructuring, but autoimmune data in 2026 renewed investor interest. Europe has NK cell developers such as Glycostem in the Netherlands and academic programmes in Germany, Norway and the UK, supported by EU advanced therapy regulations. Asia-Pacific is a major and fast-growing region. China has many NK and CAR-NK clinical trials and companies, South Korea's GC Cell and others have long histories in NK cell therapy, and Japan allows some NK treatments under its regenerative medicine law. Australia and Singapore have growing cell therapy sectors. Latin America, the Middle East and Africa have limited activity, though some clinics offer unregulated NK treatments.

Key Developments August 2026: The FDA granted regenerative medicine advanced therapy designation to AlloNK plus rituximab for refractory rheumatoid arthritis, and Artiva plans to start a phase 3 trial in the second half of 2026.
June 2026: Artiva reported that 71% of refractory rheumatoid arthritis patients with six months of follow-up in its phase 2a trial achieved ACR50 responses with its off-the-shelf NK cell therapy.
2026: Nkarta reached regulatory agreement supporting outpatient administration of its CD19 CAR-NK therapy NKX019 in community settings across several autoimmune diseases.
2024: Leading NK cell developers shifted their main programmes from cancer toward autoimmune diseases following evidence that deep B-cell depletion can produce remissions.
April 2024: ImmunityBio's IL-15 superagonist, which activates NK and T cells, was approved with BCG for BCG-unresponsive non-muscle invasive bladder cancer.
July 2024: Artiva listed on Nasdaq to fund development of its off-the-shelf NK cell therapy AlloNK in autoimmune diseases and lymphoma.

Considered in this report
• Historic Year: 2020
• Base Year: 2025
• Estimated Year: 2026
• Forecast Year: 2031

Aspects covered in this report
• Global NK Cell Therapy Market with its value and forecast along with its segments
• Various drivers and challenges
• Ongoing trends and developments
• Top profiled companies
• Strategic recommendation

By Therapy Type
• Non-Engineered NK Cell Therapies
• CAR-NK Therapies
• Other Engineered NK Therapies
• Autologous NK Cell Therapies

By Cell Source
• Umbilical Cord Blood
• Peripheral Blood
• Induced Pluripotent Stem Cells
• NK Cell Lines

By Indication
• Haematological Cancers
• Autoimmune Diseases
• Solid Tumours
• Other Indications

By End User
• Hospitals and Academic Medical Centres
• Specialised Cancer Centres
• Community Rheumatology and Oncology Practices